UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work
UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work
Read moreFri, 13th Nov 2020 14:28
UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work
Read moreSynairgen Loss Widens; Progressing On SNG001 Study For Covid-19
Read moreUK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial
Read more(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.
Read more(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times
Read moreUPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials
Read moreSynairgen Raises Cash To Go Towards Covid-19 Drug Trial
Read moreBy Paul SandleLONDON, March 18 (Reuters) - British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight aga...
Read moreSynairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19
Read more(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.
Read moreSynairgen Interim Loss Deepens On Costs As Progresses Clinical Trials
Read moreSynairgen Expects Positive Outcome From Second Part Of SNG001 Study
Read more(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in
Read more(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of
Read moreLONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,
Read more